PMID- 28254170
OWN - NLM
STAT- MEDLINE
DCOM- 20180502
LR  - 20180611
IS  - 1471-4981 (Electronic)
IS  - 1471-4906 (Linking)
VI  - 38
IP  - 9
DP  - 2017 Sep
TI  - Positive and Negative Signals in Mast Cell Activation.
PG  - 657-667
LID - S1471-4906(17)30022-4 [pii]
LID - 10.1016/j.it.2017.01.008 [doi]
AB  - Mast cells are powerful immune modulators of the tissue microenvironment. Within 
      seconds of activation, these cells release a variety of preformed biologically 
      active products, followed by a wave of mediator synthesis and secretion. 
      Increasing evidence suggests that an intricate network of inhibitory and 
      activating receptors, specific signaling pathways, and adaptor proteins governs 
      mast cell responsiveness to stimuli. Here, we discuss the biological and clinical 
      relevance of negative and positive signaling modalities that control mast cell 
      activation, with an emphasis on novel FcepsilonRI regulators, immunoglobulin E 
      (IgE)-independent pathways [e.g., Mas-related G protein-coupled receptor X2 
      (MRGPRX2)], tetraspanins, and the CD300 family of inhibitory and activating 
      receptors.
CI  - Copyright (c) 2017. Published by Elsevier Ltd.
FAU - Bulfone-Paus, Silvia
AU  - Bulfone-Paus S
AD  - Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, 
      Medicine and Health, University of Manchester, Manchester, UK.
FAU - Nilsson, Gunnar
AU  - Nilsson G
AD  - Immunology and Allergy unit, Department of Medicine, Karolinska Institutet and 
      Karolinska University Hospital, Stockholm, Sweden; Department of Medical 
      Sciences, Uppsala University, Uppsala, Sweden.
FAU - Draber, Petr
AU  - Draber P
AD  - Department of Signal Transduction, Institute of Molecular Genetics, Academy of 
      Sciences of the Czech Republic, Prague, Czech Republic.
FAU - Blank, Ulrich
AU  - Blank U
AD  - INSERM U1149, Centre de Recherche sur l'Inflammation, Paris, France; CNRS 
      ERL8252, Paris, France; Universite Paris Diderot, Sorbonne Paris Cite, Faculte de 
      Medecine, Site Xavier Bichat, Inflamex Laboratory of Excellence, Paris, France.
FAU - Levi-Schaffer, Francesca
AU  - Levi-Schaffer F
AD  - Pharmacology and Experimental Therapeutics Unit, School of Pharmacy, Institute 
      for Drug Research, Faculty of Medicine, Hebrew University of Jerusalem, 
      Jerusalem, Israel. Electronic address: francescal@ekmd.huji.ac.il.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
DEP - 20170220
PL  - England
TA  - Trends Immunol
JT  - Trends in immunology
JID - 100966032
RN  - 0 (Antimicrobial Cationic Peptides)
RN  - 0 (FCER1A protein, human)
RN  - 0 (Ki-1 Antigen)
RN  - 0 (MRGPRX2 protein, human)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (Neuropeptides)
RN  - 0 (Receptors, G-Protein-Coupled)
RN  - 0 (Receptors, IgE)
RN  - 0 (Receptors, Neuropeptide)
RN  - 0 (Tetraspanins)
SB  - IM
MH  - Animals
MH  - Antimicrobial Cationic Peptides/metabolism
MH  - *Cell Degranulation
MH  - Ganglia, Spinal/metabolism
MH  - Humans
MH  - Immunomodulation
MH  - Ki-1 Antigen/metabolism
MH  - Mast Cells/*immunology
MH  - Nerve Tissue Proteins/*metabolism
MH  - Neuropeptides/metabolism
MH  - Receptors, G-Protein-Coupled/*metabolism
MH  - Receptors, IgE/metabolism
MH  - Receptors, Neuropeptide/*metabolism
MH  - *Signal Transduction
MH  - Tetraspanins/metabolism
EDAT- 2017/03/04 06:00
MHDA- 2018/05/03 06:00
CRDT- 2017/03/04 06:00
PHST- 2016/11/28 00:00 [received]
PHST- 2017/01/17 00:00 [revised]
PHST- 2017/01/27 00:00 [accepted]
PHST- 2017/03/04 06:00 [pubmed]
PHST- 2018/05/03 06:00 [medline]
PHST- 2017/03/04 06:00 [entrez]
AID - S1471-4906(17)30022-4 [pii]
AID - 10.1016/j.it.2017.01.008 [doi]
PST - ppublish
SO  - Trends Immunol. 2017 Sep;38(9):657-667. doi: 10.1016/j.it.2017.01.008. Epub 2017 
      Feb 20.